Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

被引:0
|
作者
Zeydan, Burcu [1 ,2 ]
Azevedo, Christina J. [3 ]
Makhani, Naila [4 ,5 ]
Cohen, Mikael [6 ]
Tutuncu, Melih [7 ]
Thouvenot, Eric [8 ,9 ]
Siva, Aksel [7 ]
Okuda, Darin T. [10 ,11 ]
Kantarci, Orhun H. [2 ]
Lebrun-Frenay, Christine [6 ]
机构
[1] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Yale Sch Med, Dept Pediat, New Haven, CT USA
[5] Yale Sch Med, Dept Neurol, New Haven, CT USA
[6] Cote Azur Univ, Pasteur 2 Univ Hosp, Dept Neurol, MS Clin Nice,UR2CA URRIS, Nice, France
[7] Istanbul Univ, Cerrahpasa Sch Med, Dept Neurol, Istanbul, Turkiye
[8] Univ Montpellier, Nimes Univ Hosp Ctr, Dept Neurol, Nimes, France
[9] Montpellier Univ, IGF, CNRS, INSERM, Montpellier, France
[10] Univ Texas Southwestern Med Ctr, Neuroinnovat Program, Dallas, TX USA
[11] Univ Texas Southwestern Med Ctr, Multiple Sclerosis & Neuroimmunol Imaging Program, Dallas, TX USA
基金
美国国家卫生研究院;
关键词
RADIOLOGICALLY ISOLATED SYNDROME; INTRAMUSCULAR INTERFERON BETA-1A; 1ST DEMYELINATING EVENT; CLINICALLY DEFINITE; FOLLOW-UP; CONVERSION; ASSOCIATION; DIAGNOSIS; REVISIONS; PHASE;
D O I
10.1007/s40263-024-01117-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Radiologically isolated syndrome (RIS) is the earliest stage in the disease continuum of multiple sclerosis (MS). RIS is discovered incidentally in individuals who are asymptomatic but have typical lesions in the brain and/or spinal cord suggestive of demyelination. The 2009 and revised 2023 RIS criteria were developed for diagnosis. Presymptomatic individuals who fulfill the 2009 RIS criteria by having 3-4 of 4 dissemination in space McDonald 2005 MS criteria are still diagnosed with RIS using the revised 2023 RIS criteria. In presymptomatic individuals who do not fulfill the 2009 RIS criteria, the revised 2023 RIS criteria target to secure an accurate and timely diagnosis: In addition to (a) having one lesion in two of four locations (periventricular, juxtacortical/cortical, infratentorial, spinal cord), (b) two of three features (spinal cord lesion, cerebrospinal fluid (CSF)-restricted oligoclonal bands, and new T2 or gadolinium-enhancing lesion) should be fulfilled. Among laboratory biomarkers, CSF kappa-free light chain can also increase diagnostic accuracy. Once the diagnosis is confirmed, the established risk factors, including demographics, imaging, and laboratory biomarkers, should be evaluated for symptomatic MS transition and prognosis. Younger age, male sex, increased neurofilament-light chain, CSF abnormality, and the presence of infratentorial, spinal cord, or gadolinium-enhancing lesions on imaging are the main risk factors for transition to symptomatic MS. Two randomized clinical trials showed significant efficacy of disease-modifying treatments in delaying or preventing the development of the first clinical event in RIS. However, because some individuals remain as RIS, it is crucial to identify the individuals with a higher number of risk factors to optimize disease outcomes by early intervention while minimizing adverse events. Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance.
引用
收藏
页码:973 / 983
页数:11
相关论文
共 50 条
  • [31] Consensus recommendations on the use of follow-on disease-modifying treatments for multiple sclerosis
    Brownlee, W. J.
    Wolf, C.
    Hartung, H. -P.
    Dingermann, T.
    Anshasi, N.
    Trojano, M.
    Selmaj, K.
    Uitdehaag, B. M.
    Tur, C.
    Wuerfel, J.
    Dallmann, G.
    Witte, J.
    Sintzel, M. B.
    Bobrovnikova, O.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 362 - 363
  • [32] Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
    Lorena, Lorefice
    Maristella, Pitzalis
    Federica, Murgia
    Giuseppe, Fenu
    Luigi, Atzori
    Eleonora, Cocco
    FRONTIERS IN GENETICS, 2023, 14
  • [33] Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France
    Lebrun, C.
    Debouverie, M.
    Jeannin, S.
    Pittion-Vouyovitch, S.
    Bayreuther, C.
    Berthier, F.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (07) : 933 - 939
  • [34] Can we discontinue disease-modifying treatments in multiple sclerosis patients? Comments
    Gouider, R.
    REVUE NEUROLOGIQUE, 2017, 173 (1-2) : 44 - 46
  • [35] Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis
    Filippi-Arriaga, Francesca
    Riera-Arnau, Judit
    Rodriguez-Acevedo, Breogan
    Bosch Ferrer, Montserrat
    MEDICINA CLINICA, 2021, 156 (10): : 509 - 514
  • [36] Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis
    Renaud A. Du Pasquier
    Daniel D. Pinschewer
    Doron Merkler
    CNS Drugs, 2014, 28 : 535 - 558
  • [37] COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments
    Laroni, Alice
    Schiavetti, Irene
    Sormani, Maria Pia
    Uccelli, Antonio
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2126 - 2136
  • [38] Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis
    Du Pasquier, Renaud A.
    Pinschewer, Daniel D.
    Merkler, Doron
    CNS DRUGS, 2014, 28 (06) : 535 - 558
  • [39] Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: A systematic review
    Li, Rui
    Sun, Xiaobo
    Shu, Yaqing
    Mao, Zhifeng
    Xiao, Li
    Qiu, Wei
    Lu, Zhengqi
    Hu, Xueqiang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 12 : 23 - 28